Related Experiment Video
Updated: Apr 7, 2026
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Rifaximin Use Is Associated With Prognosis and Recurrence Patterns in Spontaneous Bacterial Peritonitis: Exploratory
Yoshihito Uchida1, Naoto Soma1, Shunsuke Yamada1
1Department of Gastroenterology & Hepatology, Faculty of Medicine Saitama Medical University Saitama Japan.
Background:
Spontaneous bacterial peritonitis (SBP) remains a life-threatening complication in cirrhotic patients with refractory ascites. Evidence for rifaximin (RFX) in SBP prevention and prognosis is lacking in Japan. We investigated the effect of RFX on prognosis and recurrence of SBP and evaluated the prognostic role of oral health within the oral-gut-hepatic axis.
Methods:
This single-center, retrospective study included 142 patients with a first SBP episode. Patients were stratified into an RFX-treated group and a non-RFX group. Outcomes included 90-day survival, SBP recurrence, and cirrhosis-related complications. Oral health status and acid-suppressive therapy were also evaluated.
Results:
Forty-seven patients received RFX. Ascitic culture positivity was comparable between groups, but RFX-treated patients had fewer enteric bacteria and more oral flora (p = 0.0033). Ninety-day survival was significantly higher with RFX (85.1% vs. 60.0%, p = 0.0023). The 12-month recurrence rate was markedly lower in the RFX-treated group (10.4% vs. 63.2%; HR 0.19, 95% CI 0.09-0.40). Oral contamination independently predicted overt hepatic encephalopathy (HR 2.56) and variceal rupture (HR 6.72). Denture use was an independent predictor of mortality (HR 2.04, 95% CI 1.23-3.38).
Conclusion:
Rifaximin use was associated with higher short-term survival and lower SBP recurrence in cirrhotic patients with refractory ascites. Oral contamination and denture use were associated with adverse outcomes, providing novel clinical evidence for the oral-gut-hepatic axis. Integration of RFX therapy with oral hygiene interventions may offer a comprehensive strategy to improve prognosis in cirrhosis.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:18Bacterial Gastroenteritis
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: